|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PRSS2 |
Gene summary for PRSS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PRSS2 | Gene ID | 5645 |
| Gene name | serine protease 2 | |
| Gene Alias | TRY2 | |
| Cytomap | 7q34 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | A6XMV9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5645 | PRSS2 | HTA12-15-2 | Human | Pancreas | PDAC | 2.63e-53 | -2.80e+00 | 0.2315 |
| 5645 | PRSS2 | HTA12-16-5 | Human | Pancreas | PDAC | 8.50e-05 | -1.10e-01 | 0.047 |
| 5645 | PRSS2 | HTA12-23-1 | Human | Pancreas | PDAC | 9.09e-39 | -2.80e+00 | 0.3405 |
| 5645 | PRSS2 | HTA12-25-1 | Human | Pancreas | PDAC | 2.08e-52 | -2.80e+00 | 0.313 |
| 5645 | PRSS2 | HTA12-26-1 | Human | Pancreas | PDAC | 7.53e-62 | -2.80e+00 | 0.3728 |
| 5645 | PRSS2 | HTA12-29-1 | Human | Pancreas | PDAC | 8.10e-141 | -2.79e+00 | 0.3722 |
| 5645 | PRSS2 | HTA12-3-16 | Human | Pancreas | PDAC | 3.93e-41 | -1.97e+00 | 0.1553 |
| 5645 | PRSS2 | HTA12-30-1 | Human | Pancreas | PDAC | 9.52e-17 | -2.80e+00 | 0.3671 |
| 5645 | PRSS2 | HTA12-32-1 | Human | Pancreas | PDAC | 2.64e-22 | -2.80e+00 | 0.3624 |
| 5645 | PRSS2 | HTA12-9-1 | Human | Pancreas | PDAC | 1.66e-85 | -2.54e+00 | 0.1532 |
| 5645 | PRSS2 | HTA12-9-2 | Human | Pancreas | PDAC | 1.38e-16 | -2.60e-01 | 0.0835 |
| 5645 | PRSS2 | HTA12-9-3 | Human | Pancreas | PDAC | 3.58e-50 | -2.60e+00 | 0.2045 |
| 5645 | PRSS2 | 4347-EC | Human | Pancreas | PanIN | 7.21e-13 | -9.38e-02 | 0.0572 |
| 5645 | PRSS2 | 4741-EC1 | Human | Pancreas | PanIN | 8.55e-16 | -1.51e-01 | 0.0223 |
| 5645 | PRSS2 | 4741-EC2 | Human | Pancreas | PanIN | 2.60e-35 | -1.34e-01 | 0.0194 |
| 5645 | PRSS2 | 181429 | Human | Pancreas | PDAC | 3.62e-26 | -2.80e+00 | 0.1416 |
| 5645 | PRSS2 | 61354830 | Human | Pancreas | PDAC | 9.52e-17 | -2.80e+00 | 0.1458 |
| 5645 | PRSS2 | DS20191261Tumor | Human | Pancreas | PDAC | 1.09e-92 | -2.80e+00 | 0.1367 |
| 5645 | PRSS2 | DS20191261TumorKeller | Human | Pancreas | PDAC | 7.94e-32 | -2.60e+00 | 0.1407 |
| 5645 | PRSS2 | Pat02-B | Human | Stomach | GC | 1.56e-50 | 9.89e-01 | 0.0368 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
| GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
| GO:001095210 | Cervix | CC | positive regulation of peptidase activity | 54/2311 | 197/18723 | 8.06e-09 | 6.99e-07 | 54 |
| GO:005254715 | Cervix | HSIL_HPV | regulation of peptidase activity | 52/737 | 461/18723 | 8.35e-12 | 6.81e-09 | 52 |
| GO:001095215 | Cervix | HSIL_HPV | positive regulation of peptidase activity | 23/737 | 197/18723 | 3.25e-06 | 1.34e-04 | 23 |
| GO:004586215 | Cervix | HSIL_HPV | positive regulation of proteolysis | 33/737 | 372/18723 | 1.25e-05 | 4.05e-04 | 33 |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0044403 | Colorectum | AD | biological process involved in symbiotic interaction | 99/3918 | 290/18723 | 1.02e-07 | 4.93e-06 | 99 |
| GO:0051701 | Colorectum | AD | biological process involved in interaction with host | 73/3918 | 203/18723 | 5.08e-07 | 1.88e-05 | 73 |
| GO:0048524 | Colorectum | AD | positive regulation of viral process | 31/3918 | 65/18723 | 1.33e-06 | 4.23e-05 | 31 |
| GO:0052126 | Colorectum | AD | movement in host environment | 63/3918 | 175/18723 | 2.85e-06 | 8.11e-05 | 63 |
| GO:0050792 | Colorectum | AD | regulation of viral process | 59/3918 | 164/18723 | 5.95e-06 | 1.52e-04 | 59 |
| GO:0046718 | Colorectum | AD | viral entry into host cell | 51/3918 | 144/18723 | 3.99e-05 | 7.16e-04 | 51 |
| GO:1903900 | Colorectum | AD | regulation of viral life cycle | 51/3918 | 148/18723 | 9.01e-05 | 1.38e-03 | 51 |
| GO:0044409 | Colorectum | AD | entry into host | 51/3918 | 151/18723 | 1.60e-04 | 2.21e-03 | 51 |
| GO:0051604 | Colorectum | AD | protein maturation | 85/3918 | 294/18723 | 6.73e-04 | 6.91e-03 | 85 |
| GO:1903902 | Colorectum | AD | positive regulation of viral life cycle | 14/3918 | 29/18723 | 9.40e-04 | 8.92e-03 | 14 |
| GO:0016485 | Colorectum | AD | protein processing | 63/3918 | 225/18723 | 6.77e-03 | 4.19e-02 | 63 |
| GO:00160321 | Colorectum | SER | viral process | 118/2897 | 415/18723 | 8.36e-12 | 1.65e-09 | 118 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05164 | Stomach | GC | Influenza A | 27/708 | 171/8465 | 9.20e-04 | 7.01e-03 | 4.94e-03 | 27 |
| hsa051641 | Stomach | GC | Influenza A | 27/708 | 171/8465 | 9.20e-04 | 7.01e-03 | 4.94e-03 | 27 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| PRSS2 | F2R | PRSS2_F2R | PARs | GC | GC |
| PRSS2 | PARD3 | PRSS2_PARD3 | PARs | GC | GC |
| PRSS2 | F2RL1 | PRSS2_F2RL1 | PARs | GC | Healthy |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PRSS2 | SNV | Missense_Mutation | novel | c.451N>G | p.Thr151Ala | p.T151A | protein_coding | tolerated(0.05) | benign(0.009) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PRSS2 | SNV | Missense_Mutation | rs763199605 | c.14N>C | p.Leu5Pro | p.L5P | protein_coding | tolerated(0.06) | possibly_damaging(0.722) | TCGA-EW-A1OV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | SD | |
| PRSS2 | insertion | Nonsense_Mutation | novel | c.673_674insGAGAAGCATCTTCATATTCACAGGAACAAGCCTTAGTTAGAT | p.Gln225delinsArgGluAlaSerSerTyrSerGlnGluGlnAlaLeuValArgTer | p.Q225delinsREASSYSQEQALVR* | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD | |||
| PRSS2 | SNV | Missense_Mutation | rs763199605 | c.14N>C | p.Leu5Pro | p.L5P | protein_coding | tolerated(0.06) | possibly_damaging(0.722) | TCGA-FU-A3NI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PRSS2 | SNV | Missense_Mutation | novel | c.29N>C | p.Val10Ala | p.V10A | protein_coding | tolerated(0.1) | benign(0.005) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| PRSS2 | SNV | Missense_Mutation | rs761488443 | c.112N>A | p.Gln38Lys | p.Q38K | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AH-6644-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| PRSS2 | SNV | Missense_Mutation | rs773808187 | c.325C>T | p.Arg109Cys | p.R109C | protein_coding | tolerated(0.09) | benign(0.074) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| PRSS2 | SNV | Missense_Mutation | novel | c.198G>T | p.Lys66Asn | p.K66N | protein_coding | tolerated(0.09) | benign(0.096) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| PRSS2 | SNV | Missense_Mutation | novel | c.677G>A | p.Gly226Glu | p.G226E | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PRSS2 | SNV | Missense_Mutation | novel | c.290G>T | p.Gly97Val | p.G97V | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5645 | PRSS2 | DRUGGABLE GENOME, PROTEASE, ENZYME | DERMOLASTIN | |||
| 5645 | PRSS2 | DRUGGABLE GENOME, PROTEASE, ENZYME | CYANOPEPTOLIN S | CYANOPEPTOLIN S | ||
| 5645 | PRSS2 | DRUGGABLE GENOME, PROTEASE, ENZYME | CYANOPEPTOLIN SS | CYANOPEPTOLIN SS | ||
| 5645 | PRSS2 | DRUGGABLE GENOME, PROTEASE, ENZYME | BORTEZOMIB | BORTEZOMIB | 20875739 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |